Answers are grounded in this paper and cite their sources.
We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.
No takes yet. Share an insight, caveat, or question.
Achar et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: